How drug discovery will fight over who gets credit for AI contributions
Bloomberg Law examines a fast-emerging legal and commercial question: how to assign credit when AI contributes to drug discovery. As AI becomes more embedded in discovery pipelines, questions about inventorship, attribution, and value-sharing are moving from theory to contract terms.
The legal problem of crediting AI contributions in drug discovery may become one of the field’s most consequential unresolved issues. In an industry built on patents, licensing, and milestone payments, attribution is not a philosophical debate; it determines ownership, revenue, and control.
As AI systems become more involved in generating hypotheses, ranking targets, and designing candidate structures, companies will increasingly need to define what counts as human invention versus machine assistance. That distinction matters for patent strategy, internal governance, and partnerships with AI vendors or platform developers.
This issue also reveals a deeper tension in the industry’s business model. If AI materially contributes to a drug candidate, who captures the value: the pharma company running experiments, the biotech that built the model, the cloud provider hosting the workflow, or the researchers interpreting the output? The answer is rarely simple, and it may vary by jurisdiction.
That makes legal infrastructure a competitive advantage. The companies that can document AI’s role clearly, structure contracts carefully, and preserve defensible patent claims may be better positioned to convert AI-assisted science into durable commercial assets.